Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study.

IF 3.8 3区医学 Q1 REPRODUCTIVE BIOLOGY

Journal of Ovarian Research Pub Date : 2025-05-27 DOI:10.1186/s13048-025-01695-2

Yuta Endo, Yoshiaki Takagawa, Yuki Yoshimoto, Masanori Machida, Yuntao Dai, Yusuke Azami, Ichiro Seto, Kanako Takayama, Motohisa Suzuki, Tatsuhiko Nakasato, Yasuhiro Kikuchi, Takahiro Kato, Akiko Yamaguchi, Shu Soeda, Keiya Fujimori, Masao Murakami

{"title":"Proton beam therapy achieves excellent local control for recurrent epithelial ovarian cancer: a single-center retrospective study.","authors":"Yuta Endo, Yoshiaki Takagawa, Yuki Yoshimoto, Masanori Machida, Yuntao Dai, Yusuke Azami, Ichiro Seto, Kanako Takayama, Motohisa Suzuki, Tatsuhiko Nakasato, Yasuhiro Kikuchi, Takahiro Kato, Akiko Yamaguchi, Shu Soeda, Keiya Fujimori, Masao Murakami","doi":"10.1186/s13048-025-01695-2","DOIUrl":null,"url":null,"abstract":"Background: Previous studies have demonstrated the benefit of radiation therapy for patients with recurrent epithelial ovarian cancer; however, the effects of proton beam therapy in these patients remain unelucidated. This study aimed to evaluate the use of proton beam therapy in recurrent epithelial ovarian cancer and to identify factors predictive of local control.Results: This retrospective study included 13 patients with a total of 30 lesions who underwent proton beam therapy for recurrent epithelial ovarian cancer at our institution between October 2008 and March 2021. The median age of the patients at the initial proton beam therapy was 62 (range, 42-82) years. Eight patients had stage III or IV disease, and seven had serous carcinoma; ten patients exhibited platinum resistance. The irradiated sites included 16 lymph nodes and 9 pelvic or abdominal masses. The median tumor size and maximum standardized uptake value (SUVmax) of fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) were 25 (range, 9-83) mm and 12.6 (range, 3.9-25.1), respectively. The median total dose was 65 (range, 45-72) Gy (relative biological effectiveness). The 1- and 2-year local control were 91.5% and 71.3%, respectively. The SUVmax of 18F-FDG-PET/CT was a significant predictor of local control (cutoff value, 17.7). The median progressing-free and overall survival after proton beam therapy initiation were 9.6 and 21.5 months, respectively. No grade 3 or higher proton beam therapy-induced adverse events were observed.Conclusion: Proton beam therapy demonstrated excellent local control of recurrent epithelial ovarian cancer, with tolerable toxicity, suggesting that this modality may represent a promising treatment option. The SUVmax of 18F-FDG-PET/CT performed prior to proton beam therapy may serve as a predictor of local control.Clinical trial number: Not applicable.","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"110"},"PeriodicalIF":3.8000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12108022/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ovarian Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13048-025-01695-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Previous studies have demonstrated the benefit of radiation therapy for patients with recurrent epithelial ovarian cancer; however, the effects of proton beam therapy in these patients remain unelucidated. This study aimed to evaluate the use of proton beam therapy in recurrent epithelial ovarian cancer and to identify factors predictive of local control.

Results: This retrospective study included 13 patients with a total of 30 lesions who underwent proton beam therapy for recurrent epithelial ovarian cancer at our institution between October 2008 and March 2021. The median age of the patients at the initial proton beam therapy was 62 (range, 42-82) years. Eight patients had stage III or IV disease, and seven had serous carcinoma; ten patients exhibited platinum resistance. The irradiated sites included 16 lymph nodes and 9 pelvic or abdominal masses. The median tumor size and maximum standardized uptake value (SUVmax) of fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) were 25 (range, 9-83) mm and 12.6 (range, 3.9-25.1), respectively. The median total dose was 65 (range, 45-72) Gy (relative biological effectiveness). The 1- and 2-year local control were 91.5% and 71.3%, respectively. The SUVmax of ¹⁸F-FDG-PET/CT was a significant predictor of local control (cutoff value, 17.7). The median progressing-free and overall survival after proton beam therapy initiation were 9.6 and 21.5 months, respectively. No grade 3 or higher proton beam therapy-induced adverse events were observed.

Conclusion: Proton beam therapy demonstrated excellent local control of recurrent epithelial ovarian cancer, with tolerable toxicity, suggesting that this modality may represent a promising treatment option. The SUVmax of ¹⁸F-FDG-PET/CT performed prior to proton beam therapy may serve as a predictor of local control.

Clinical trial number: Not applicable.

查看原文本刊更多论文

质子束治疗对复发性上皮性卵巢癌取得了良好的局部控制：一项单中心回顾性研究。

背景：先前的研究已经证明放射治疗对复发性上皮性卵巢癌患者有益；然而，质子束治疗对这些患者的影响尚不清楚。本研究旨在评估质子束治疗在复发性上皮性卵巢癌中的应用，并确定预测局部控制的因素。结果：本回顾性研究纳入了2008年10月至2021年3月期间在我院接受质子束治疗复发性上皮性卵巢癌的13例患者，共30个病灶。初始质子束治疗患者的中位年龄为62岁（范围42-82岁）。8例为III期或IV期，7例为浆液性癌；10例患者出现铂耐药。放疗部位包括16个淋巴结和9个盆腔或腹部肿块。氟-18-氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描（18F-FDG-PET/CT）的中位肿瘤大小和最大标准化摄取值（SUVmax）分别为25（范围9-83）mm和12.6（范围3.9-25.1）。中位总剂量为65 Gy（范围45-72）（相对生物有效性）。1年和2年局部控制率分别为91.5%和71.3%。18F-FDG-PET/CT的SUVmax是局部控制的重要预测因子（临界值为17.7）。质子束治疗开始后的中位无进展生存期和总生存期分别为9.6个月和21.5个月。未观察到3级或更高级别质子束治疗引起的不良事件。结论：质子束治疗对复发性上皮性卵巢癌表现出良好的局部控制，毒性可耐受，表明这种治疗方式可能是一种有希望的治疗选择。质子束治疗前进行的18F-FDG-PET/CT的SUVmax可以作为局部控制的预测因子。临床试验号：不适用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ovarian Research REPRODUCTIVE BIOLOGY-

CiteScore

6.20

自引率

2.50%

发文量

125

审稿时长

>12 weeks

期刊介绍： Journal of Ovarian Research is an open access, peer reviewed, online journal that aims to provide a forum for high-quality basic and clinical research on ovarian function, abnormalities, and cancer. The journal focuses on research that provides new insights into ovarian functions as well as prevention and treatment of diseases afflicting the organ. Topical areas include, but are not restricted to: Ovary development, hormone secretion and regulation Follicle growth and ovulation Infertility and Polycystic ovarian syndrome Regulation of pituitary and other biological functions by ovarian hormones Ovarian cancer, its prevention, diagnosis and treatment Drug development and screening Role of stem cells in ovary development and function.